MedTrace Logo

Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease

NCT01032486 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2013-08-28

No results posted yet for this study

Summary

The main objective of this study is to evaluate the effect of Azilect® on sleep disturbances in Parkinson's Disease patients, after 2 months of treatment.

Conditions

Interventions

DRUG

Rasagiline mesylate

Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Michel Panisset, MD · André Barbeau Movement Disorders Unit, Centre Hospitalier Université de Montréal (CHUM)

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-06-30
Completion
2011-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01032486 on ClinicalTrials.gov